Could you be at risk of rabies, typhoid fever, chikungunya, or cholera while travelling?
Search your destination
to find out.
Risk of exposure to rabies, typhoid fever,
chikungunya, and cholera
Find out how vaccination can help protect you and your
family against rabies, typhoid fever, chikungunya, and
cholera during your travels
RabAvert® can help protect adults and children from rabies.
RabAvert (Rabies Vaccine) is indicated for:
- Pre-exposure vaccination, in both primary series and booster doses against rabies in all age groups.
- Post-exposure prophylaxis against rabies in all age groups.
Once symptoms of rabies appear, it is fatal in almost 100% of cases.
Note: RabAvert is not a treatment for rabies or its complications, including death.
VIVOTIF® is the only oral typhoid fever vaccine.
VIVOTIF is an oral vaccine for protection of adults and children older than 5 years against typhoid fever, a disease caused by bacteria called Salmonella enterica serovar Typhi (abbr. S. typhi).
Typhoid fever is spread by consuming contaminated food or water.
Note: VIVOTIF is not a treatment for typhoid fever or its complications.
VIMKUNYA® is the first and only virus-like particle vaccine to help protect against the chikungunya virus.
VIMKUNYA is a vaccine for intramuscular injection for use in individuals 12 years of age and older to help protect against chikungunya virus (CHIKV).
Joint pain caused by chikungunya can be debilitating and last weeks, months, or years.
Note: VIMKUNYA is not a treatment for chikungunya or its complications.
VAXCHORA® is the only one-dose cholera vaccine.
VAXCHORA is a single-dose oral vaccine that helps protect people aged 2–64 from cholera. The vaccine is effective against the most common serogroup of cholera (O1) but does not work against uncommon serogroups such as O139.
If left untreated, cholera can cause severe diarrhea, dehydration, and even death.
Note: VAXCHORA is not a treatment for cholera or its complications, including dehydration or death.
Important safety information
RabAvert
RabAvert is indicated for:
Pre-exposure vaccination against rabies in all age groups, in both primary series and booster doses.
Post-exposure prophylaxis against rabies in all age groups.
Like all vaccines, RabAvert may not fully protect all people who are vaccinated. History of anaphylaxis to the vaccine or any of the vaccine components, including the container, constitutes a contraindication to pre-exposure vaccination. In view of the almost invariably fatal outcome of rabies, there are no contraindications to post-exposure prophylaxis, including pregnancy.
Anaphylaxis and neuroparalytic events such as encephalitis, transient paralysis, and Guillain-Barré Syndrome have been reported to be temporally associated with the use of RabAvert. Your risk of developing rabies must be carefully considered, however, before deciding to discontinue immunization.
The most commonly occurring adverse reactions are injection-site reactions—such as swelling and pain; flu-like symptoms—such as fatigue, fever, headache, dizziness, weakness, and rash, that may also be red, lumpy, itchy (very common—may affect more than 1 in 10 people); injection-site redness, abdominal pain, lymph node swelling, muscle pain and general discomfort, joint pain, nausea, vomiting, diarrhea, and decreased appetite (common—may affect up to 1 in 10 people).
In rare cases (may affect up to 1 in 1,000 people), chills and sweating, circulatory reactions—such as hot flush—visual disturbance, tingling or numbness of skin, pain in limbs, feeling faint, fainting, and hypersensitivity have been reported. This is not a complete list of side effects. If you experience unexpected effects while taking RabAvert, contact your healthcare professional.
Serious allergic reactions are rare after receiving a vaccine. These reactions may include:
difficulty in breathing,
blue discolouration of the tongue or lips,
swelling of the face and neck or elsewhere,
low blood pressure causing collapse and shock.
When these signs or symptoms occur, they usually develop very quickly after the injection is given; consult a doctor immediately.
Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild general adverse reactions to rabies vaccine. Usually, such reactions subside within a few days and may be successfully managed with anti-inflammatory and fever-reducing agents.
For more information, please consult the Product Monograph at bn-na.com/rabavert-consumer-en. Ask your healthcare professional if RabAvert is suitable for you.
VIVOTIF
VIVOTIF is an oral vaccine for protection of adults and children older than 5 years against typhoid fever, a disease caused by bacteria called Salmonella enterica serovar Typhi (abbr. S. typhi). Immunization may not be suitable for everyone and can be associated with adverse events. 100% protection cannot be guaranteed. VIVOTIF is not a treatment for typhoid fever or its complications. The vaccine should not replace standard preventive measures such as handwashing and avoiding potentially contaminated food and water. The safety of VIVOTIF has not been demonstrated in people with compromised immune responses (including in those treated with immunosuppressive drugs) and should not be used by them regardless of the benefits.
The most commonly reported side effects of VIVOTIF during clinical studies were: stomach pain, feeling or being sick (nausea and vomiting), diarrhea, fever, flu-like symptoms, headache, and rash.
Side effects that have been reported very rarely during normal use include: skin irritation, rashes, red or lumpy raised rashes, itching and hives, severe allergic reactions with drops of blood pressure and loss of consciousness, weakness, generally feeling unwell, shivering, tiredness, pins and needles, dizziness, joint and muscle pain.
These symptoms disappear spontaneously within a few days. This is not a complete list of side effects. For any unexpected effects while taking VIVOTIF, contact your healthcare professional.
For more information, including full dosing information, please consult the Product Monograph at bn-na.com/vivotif-consumer-en. Ask your healthcare professional if VIVOTIF is suitable for you.
VIMKUNYA
VIMKUNYA is a vaccine for intramuscular injection for use in individuals 12 years of age and older to help protect against chikungunya virus (CHIKV). Following a single dose of VIMKUNYA, it usually takes between one to two weeks to be protected against chikungunya virus. Immunization may not be suitable for everyone. As with all vaccines, 100% protection is not guaranteed. VIMKUNYA is not a treatment for chikungunya virus or its complications.
Speak to your healthcare professional about how long protection from VIMKUNYA may last prior to re-exposure to the chikungunya virus. Since 100% protection cannot be guaranteed, you should still take steps to avoid mosquito bites. VIMKUNYA does not protect against other diseases transmitted by mosquitoes.
Immunization can be associated with adverse events, including fatigue, headache, and muscle pain. Chills, joint pain, malaise, and nausea may also occur. You may feel pain at the injection site. Speak with a healthcare professional immediately if you experience any of the following serious side effects: difficulty breathing, hoarseness or wheezing, hives, dizziness, weakness, or fast heartbeat.
For more information, including full dosing information, please consult the Product Monograph at bn-na.com/vimkunya-consumer-en. Ask your healthcare professional if VIMKUNYA is suitable for you.
VAXCHORA
VAXCHORA is a single-dose oral vaccine that helps protect people aged 2–64 from cholera. VAXCHORA should be taken at least 10 days before travelling to an area where there is a risk of diarrhea caused by cholera. VAXCHORA is effective against the most common serogroup of cholera (O1) but is not effective against uncommon serogroups such as O139. Immunization may not be suitable for everyone and can be associated with adverse events. 100% protection cannot be guaranteed.
VAXCHORA is not a treatment for cholera or its complications. The vaccine should not replace standard preventive measures such as handwashing and avoiding potentially contaminated food and water.
The most common side effects of VAXCHORA are tiredness, headache, nausea/vomiting, abdominal pain, and lack of appetite. Allergic reactions can also occur. Contact a doctor immediately if you experience the following serious side effects: swelling of the face or throat, hives, itchy rash, breathlessness, and/or a drop in blood pressure and fainting.
VAXCHORA vaccine may be shed in the stool of recipients for at least 7 days and could be transmitted to non-vaccinated close (household) contacts. Use with caution if you have immunocompromised close contacts.
For more information, including full step-by-step instructions for preparing VAXCHORA, please consult the Product Monograph at bn-na.com/vaxchora-consumer-en. Ask your healthcare professional if VAXCHORA is suitable for you.
